PO.PR02.02 · 预防研究
PanGIA分析系统:一种通过口腔样本对口腔癌进行无创诊断的新型机器学习平台
PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
PanGIA分析系统(PAS)是一种先进的诊断平台,旨在通过机器学习辅助的生化图谱分析来表征复杂的生物系统。PAS由经过训练的算法和称为NuTec Slides的专有水凝胶微阵列驱动,能够从多种生物体液中无偏倚地捕获和分析生物分子特征。口腔样本是一种特别有价值但尚未充分开发的无创疾病评估基质,可提供对局部和全身健康状况的洞察。在本研究中,评估了一款可商业化的PAS原型区分加入癌症标志物和未加入癌症标志物口腔样本的能力。将健康志愿者的口腔液与TruSample口腔缓冲细胞混合,并加入文献验证的、代表口腔癌的分析物组合。将NuTec Slides与加标和未加标对照样本孵育后,进行基于热的信号显影和高分辨率扫描。提取的图像特征数据通过主成分分析(PCA)进行分析。这项概念验证研究表明,PAS能够区分含有文献支持的口腔癌分析物的加标人类口腔样本与对照样本。结论:这些发现确立了PAS通过口腔液图谱分析进行无创癌症检测的概念验证。有必要进一步开展临床验证,以扩展其在其他癌症类型中的诊断应用,并探索其在纵向监测、风险分层和个性化医疗方面的潜力。
查看英文原文 English abstract
The PanGIA Analysis System (PAS) is an advanced diagnostic platform designed to characterize complex biological systems through machine learning-assisted biochemical profiling. Powered by trained algorithms and proprietary hydrogel microarrays known as NuTec Slides, PAS enables unbiased capture and analysis of biomolecular signatures from diverse biofluids. Oral samples represent a particularly valuable yet underexplored matrix for noninvasive disease assessment, offering insight into both local and systemic health conditions. In this study, a commercialization-ready PAS prototype was evaluated for its capacity to differentiate between cancer-spiked and unspiked oral samples. Oral fluid from healthy volunteers was pooled with TruSample Oral Buffer Cell and spiked with literature-validated analyte panels representative of oral cancer. Following incubation of NuTec Slides with both spiked and unspiked control samples, heat-based signal development and high-resolution scanning were performed. Extracted image feature data were analyzed by principal component analysis (PCA). This proof-of-concept study indicates that PAS can distinguish between control and spiked human oral samples containing literature supported oral cancer analytes. Conclusion: These findings establish proof-of-concept for the use of PAS in noninvasive cancer detection through oral fluid profiling. Further clinical validation is warranted to expand its diagnostic applications across additional cancer types and to explore its potential in longitudinal monitoring, risk stratification, and personalized medicine.
利益披露 Disclosure
F. Lim,
PanGIA Biotech Inc. Employment.
A. Nagesetti,
PanGIA Biotech Inc. Employment.
N. Gonzalez,
PanGIA Biotech Inc. Employment.
M. Javiel,
PanGIA Biotech Inc. Employment.
P. Hernandez,
PanGIA Biotech Inc. Employment.
K. Ambert,
PanGIA Biotech Inc. Employment.
R. Cardwell,
PanGIA Biotech Inc. Employment, g., Board of Directors, non-salaried role), Stock.
O. Piloto,
PanGIA Biotech Inc. Employment, g., Board of Directors, non-salaried role), Stock.